BioNexus Gene Lab Corp BGLC
Medical Specialities · data as of November 13, 2026
BioNexus Gene Lab Corp (BGLC) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $3M and net income of -$3M, a net margin of -82.4%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -8% a year, a 5-year average ROIC of -14%.
About BioNexus Gene Lab
BioNexus Gene Lab is listed in the US and classified in medical specialities. Revenue went from $212328 in 2018 to $7M in 2025, growth of about 66.2% a year. It was profitable in 3 of the last 8 years in our data. It spends 1% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $7M | $10M | $10M | $11M | $13M | $11M | $126955 | $212328 |
| Net income | -$3M | -$3M | -$2M | -$3M | -$355966 | $751571 | $1M | -$246469 | $26454 |
| Free cash flow | -$853600 | -$2M | -$2M | -$2M | $551822 | $5999 | $131059 | -$230090 | -$313701 |
| EPS (diluted) | $-0.88 | $-1.02 | $-0.09 | $-0.17 | — | — | $0.01 | $0.00 | $0.00 |
| Net margin | -82.4% | -40.2% | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% | -194.1% | 12.5% |
| ROIC | — | -33.7% | -18.4% | -26.3% | -3.6% | 11.6% | 15.0% | -19.0% | 3.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does BioNexus Gene Lab pay a dividend?
Not currently.
Is BioNexus Gene Lab a good stock to buy?
We do not give buy or sell advice. BioNexus Gene Lab scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.